drug-device combination product,GEM 21S®Growth-factor Enhanced Matrix, received US Food and Drug
securities research analyst reports, US sales of bone grafting products
generate drug-device combination products that provide results superior
gives effect to our sale of shares of common stock in this
us to obtain or maintain regulatory approval to market our product or
one product candidate has negative clinical trial results or is shown
development, use and marketing ofGEM 21Sand all of ourGEMproduct candidates are governed by a series of licensing
products.12Table of ContentsOur rights to use technologies licensed to
of our clinical trials, regulatory approval of our product candidates
Based on our current forecasts forGEM 21S, our planned clinical study programs forGEM OS1and other product candidates and our anticipated pre-clinical studies,
generate sales of our products in the future, our business, financial
approved products fails to achieve market acceptance, our ability to
product candidates in clinical trials and the sale of any approved
product candidates require FDA authorization by means of an approval or
receive regulatory approval to commercialize the product candidate.
regulatory approvals of any products that we develop, license or
additional capital in the future, our product development could be
shares of our common stock or are perceived by the market as intending
shares of common stock had piggyback registration rights with respect
stockholders holding approximately 280,000 shares of our common stock.
of clinical studies and eventual FDA approval of our product candidates
million, based on the last reported sales price for our common stock on
proceeds from the sale of shares of common stock by the selling
proceeds from the sale of shares of common stock by the selling
Nasdaq Global Market for shares of our common stock since inception of
common stock being offered hereby (based on the last reported sales
average number of shares of common stock outstanding,
relate to our product candidates in clinical development, such as
compensation cost for all share-based payments granted subsequent to
factor of the expected market price of our common stock of 80%;
account for share-based compensation under APB Opinion No. 25.The employee stock options granted by us are structured to
extent the deemed fair value of our shares of common stock for
Financial Accounting Standards Board Statement No. 123,’’ we provide pro forma disclosure of the effect
in determining the estimated value of our common stock under SFAS No. 123, as amended.
estimated the fair value of stock options issued to employees using the
$25  million to compensate us for the cost of product development
milestones of the products developed under the agreement.
no compensation cost for employee stock options issued at fair market
received US marketing approval of our first product for bone
supply agreements covering the two main components of ourGEMproduct and product candidates, β-TCP and rhPDGF.
fees (including in the form of grants of stock options) to, and
development, marketing and distribution partnership with Luitpold forGEM 21S.The exclusive sublicense agreement
clinical trials, certain regulatory filings, product approvals, and/or
cover the composition and use of tissue growth factors.GEM 21Sand our lead product candidates are protected by patents we have
paid ZymoGenetics an initial license fee in shares of our common stock,
combination products companies, including major pharmaceutical
be required to gain market approval as a medicinal product as a result
compensation plans are as provided for below:2001 Long-term Stock Incentive
number of shares of common stock covered by options or
stock options for all employees, including members of executive
In January 2004, we granted Mr. Bullock options to purchase 112,500 shares of our common stock
common stock, pursuant to the terms of his employment agreement.
shares of our common stock), based on satisfactory performance of
options to purchase 24,000 shares of our common stock.
options to purchase 24,000 shares of our common stock.
was granted options to purchase 37,500 shares of our common stock.
was granted options to purchase 37,500 shares of our common stock.
preferred stock at a purchase price of $2.53 per share for an aggregate
preferred stock at a purchase price of $4.79 per share to investors for
convertible preferred stock at a purchase price of $7.87 per share to
Under prior agreements, we compensated Dr. Friedlaender for his consulting through stock option grants.
will sell additional shares of common stock to cover
shares of common stock.(10)Includes
shares of common stock.(10)Includes
options to purchase 2,430 shares of common stock.(17)Includes
options to purchase 2,430 shares of common stock.(17)Includes
options to purchase 2,430 shares of common stock.(17)Includes
shares of our common stock at a weighted average exercise price of
shares of our common stock at a weighted average exercise price of
registration under the Securities Act of shares of common stock.
following respective number of shares of common stock at a
propose to offer the shares of common stock to the public at
additional shares of common stock,
above table bears to the total number of shares of common stock
Stock Purchase Plan, and we may issue shares of our common
Company’s product candidates in clinical development, such as
manufacture of clinical material, product related consultants, contract
manufacture of clinical material, product related consultants, contract
the Company had continued to account for share-based compensation under
includes $184,220 and $518,964 of stock-based compensation costs,
results.The Company currently sells its only product through an
Board of Directors approved the adoption of the 2001 Long-Term Stock
Long-Term Stock Incentive Plan(continued)key personnel and consultants of the Company
liquidation value per share of the Company’s common stock had
into shares of common stock would be subject to lock-up agreements with
years.Under the Option Plan, 2,250,000 shares of common stock at
the nine months ended September  30,  2006 and 2005.Stock Options Granted to Board Members (Non-Employees)The Company granted 15,406 and 11,408 options to members
Long-Term Stock Incentive Plan(continued)The Company has recorded professional
of stock-based compensation expense for the Purchase Plan during the
services to the Company relating to the use of biological products to
Company’s orthopedic product development, operating losses are
share-based payments to employees or directors, including grants of
share-based payments to employees or directors, including grants of
employee and director stock options, to be recognized as an expense on
employee and director stock options, to be recognized as an expense on
SFAS 123, the Company currently accounts for share-based payments to
The agreement sets forth the pricing for the products, and provides for
The agreement sets forth the pricing for the products, and provides for
execution of the research, development and marketing agreement,
execution of the research, development and marketing agreement,
payment to Harvard under the Company’s license agreement.The FDA approval of the Company’s product,GEM 21S,
FDA approval, the Company was required to pay milestone payments
the agreement, the annual product prices the Company is obligated to
issued an additional 362,319 shares of Series  A Preferred Stock
are convertible into shares of common stock of the Company on a 1 to 1
convert into shares of common stock of the Company on a 1 to 1 basis
preferred stock and is included in the Company’s total costs of
will automatically convert into shares of common stock of the Company
will automatically convert into shares of common stock of the Company
Board of Directors to issue preferred stock and determine its rights
outstanding shares of common and Preferred Stock also are party to a
outstanding shares of common and Preferred Stock also are party to a
fair value of common stock, the Company’s Board of Directors
additional 3,750 options for common stock to other non-employees at an
No. 123.The Company has reserved shares of common stock for
shares of Series  A Preferred Stock, the Company entered into a
public offering of shares of its common stock.
to purchase 1,503,902 shares of common stock were outstanding under our